AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04305977 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WAVE-TW
Description: The WAVE-TW open pilot trial of the intervention consists of 5 sessions conducted individually with each part participant. Each session lasts approximately 30-50 minutes. The first session will be the LifeSteps Adherence session that focuses on cognitive-behavioral and problem-solving techniques to promote adherence. The next four sessions will be dedicated to trauma writing.
Study NCT00613431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS8080
Description: CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
Study NCT04452539 — intervention group
Intervention type: PROCEDURE
Intervention: Paediatric cardiac surgery
Description: All patients undergoing paediatric cardiac surgery
Study NCT00613431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Some subjects will receive matching placebo instead of CS-8080.
Study NCT02008994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genomic and Proteomic Profiling
Description: Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
Study NCT02034643 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: balloon pressure adjustment
Description: Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
Study NCT02747758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
Study NCT02962817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Study NCT02962817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video explaining the clinical practice guidelines on low back pain
Study NCT04134273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLPG Topical Gel 1%
Description: Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
Study NCT04134273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin Phosphate topical gel 1%
Study NCT04134273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study NCT00855400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminectomy and bone marrow stem cells transplantation
Description: T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
Study NCT00855400 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cells collection
Description: Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
Study NCT02316249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
Study NCT02316249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
Study NCT03580122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Aspartate
Description: Asparten
Study NCT03736213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Description: In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. I
Study NCT03736213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ultrasound biofeedback
Description: In ultrasound biofeedback, the elements of traditional articulatory treatment are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
Study NCT00765011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF, radiotherapy and cetuximab
Description: 3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
Study NCT00765011 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: H&N surgery
Description: Rescue surgery
Study NCT03961022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal supplement: ReWin(d) vs Placebo
Description: Supplementation during 4 weeks + 72 hours post acute exercice
Study NCT03961022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polyherbal supplement: ReWin(d) vs Placebo
Description: Supplementation during 4 weeks + 72 hours post acute exercice
Study NCT00351598 — intervention group
Intervention type: RADIATION
Intervention: Definitive Radiotherapy
Description: 60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
Study NCT03582280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate (ACC) - Amor
Description: Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
Study NCT03036553 — intervention group
Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
Study NCT03983252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT01953939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prosthetic Limb Users
Description: There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
Study NCT01922167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Study NCT01922167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Study NCT00123955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25mg tablet daily for 9 months
Study NCT00123955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 9 months
Study NCT00365937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunological peptides and immunological adjuvants
Study NCT00365937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A2 peptides
Description: Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
Study NCT00365937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA51
Description: Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
Study NCT00365937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMP321
Description: Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials.
Study NCT02756247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Study NCT02756247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT01565616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Regimen with Bone Marrow Transplant
Description: The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV
Study NCT02254369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC021109
Study NCT02254369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02747758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
Study NCT02747758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (tDCS)
Description: transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
Study NCT02350218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eglandin
Description: Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
Study NCT02350218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eglandin
Description: Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
Study NCT03351946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP
Description: Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
Study NCT03351946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
Study NCT01999933 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
Study NCT01999933 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
Study NCT01999933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin（DDP） weekly
Description: concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
Study NCT00375570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Topical treatment 5 times daily for 5 days
Study NCT00362921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel wafers in combination with O6-benzylguanine
Study NCT01999933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin
Description: concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
Study NCT01999933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin
Description: adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
Study NCT00246363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Silymarin (milk thistle)
Study NCT00246363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02850978 — intervention group
Intervention type: DRUG
Intervention: Spiolto
Study NCT02669589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT02669589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate
Study NCT00881894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
Study NCT00776360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: 80mIE/min as continuous infusion for 70 minutes
Study NCT00776360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 80mIE/min as continuous infusion for 70 minutes
Study NCT00776360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: 80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
Study NCT00776360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: 80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
Study NCT03431597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: novel micronutrient
Description: The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
Study NCT03431597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: existing micronutrient supplement, UNIMMAP
Description: UNIMMAP will be provided in tablet form and given one daily
Study NCT04068922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Intervention
Description: Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
Study NCT01478932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing retraining
Description: In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
Study NCT01478932 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Promotion
Description: n-person instructions will be given about what the intervention includes. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, health promotion topics will be discussed (lipid profile, healthy eating to improve lipid profile, importance of regular doctor visits, cancer screening, and so forth).
Study NCT01832610 — intervention group
Intervention type: DEVICE
Intervention: HeartWare® VAS
Description: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
Study NCT03844308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isha Kriya Meditation
Description: Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
Study NCT03844308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Isha Kriya Meditation
Description: Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
Study NCT02365259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
Study NCT02365259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
Study NCT04691310 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
Study NCT03445312 — intervention group
Intervention type: BEHAVIORAL
Intervention: not processing urine cultures
Description: microbiology lab will not process culture unless called
Study NCT00761345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
Study NCT04691310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tex Gold
Description: The Kinesio Tex Gold is a kinesio tape that had been certified and patented.
Study NCT02801084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced environmental stimulation
Description: Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 \& 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart.
Study NCT00761345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100mg or 150mg daily of each 21 day cycle
Study NCT00761345 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose fractionated radiotherapy
Description: low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
Study NCT01911455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acamprosate
Study NCT01911455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01914250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic effect of topical tetracaine 2 %
Description: The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist